Recent Advances in Stimuli-responsive Hybrid Natural, Synthetic, and Inorganic Biomaterial Platform Systems for DiverseCancer Immunotherapy and Therapeutic Applications

Abstract

Cancer immunotherapy is a breakthrough in modern oncology, which uses immune system to identify and kill tumor cells. However, clinical efficacy is still hindered by barriers such as immune evasion, insufficient
tumor targeting, poor therapeutic efficacy, and systemic toxicity. Recent advances in stimuli-responsive hybrid biomaterial platform systems based on inorganic, synthetic, and natural materials have been promising
for improved therapeutic applications and cancer immunotherapy. These smart biomaterials are designed to respond specifically to exterior stimuli such as light, temperature, magnetic fields, ultrasound, and to internal
stimuli such as pH, redox potential, enzymes, hypoxia, and reactive oxygen species. This responsiveness allows controlled and localized drug release, reducing off-target effects and improving the efficacy of treatment. This
responsiveness lowers off-target effects and promotes treatment efficacy by facilitating controlled and site- specific release of medicines. Natural biomaterials such as chitosan, collagen, gelatin, alginate, and hyaluronic
acid have better biocompatibility, biodegradability, and immunomodulatory properties. Synthetic polymers such as polycaprolactone, polyethylene glycol, and poly(lactic-co-glycolic acid) confer structural stability, tunable mechanical properties, and extended drug release. Inorganic nanomaterials such as gold nanoparticles,
mesoporous silica nanoparticles, iron oxide nanoparticles, and metal organic frameworks were applied to enhance drug loading efficiency, photothermal conversion, imaging capability, and magnetic responsiveness. The incorporation of these materials into hybrid systems has enabled multifunctional nanoparticles, injectable hydrogels, biomimetic carriers, and theranostic platforms for combined chemotherapy, photothermal therapy, photodynamic therapy, gene therapy, and immune checkpoint blockade. Stimuli-responsive hybrid biomaterials in the tumor microenvironment dramatically increase antigen presentation, dendritic cell activation, T-cell-mediated
immune responses, and immunogenic cell death. New technologies such as biomimetic engineering, multi-stimuli- responsive nanomedicine, and artificial intelligence-assisted biomaterial design further expedite the development of next-generation precision medicines. Despite challenges associated with biosafety, large-scale fabrication, and clinical translation, these advanced biomaterial platforms hold great promise to enhance
outcomes in cancer treatment and further the field of personalized cancer immunotherapy